ArticleACS omega2025
Functionalized Silk Fibroin and Mucin Hybrid Material for Targeted EGF and Papain Delivery in Wound Healing.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silk fibroin (SF) and mucin are extensively recognized as promising biomaterials for wound dressings due to their outstanding biocompatibility, biodegradability, and ability to support cell growth and tissue regeneration. In this study, we developed a hybrid SF/mucin wound dressing (HYB) using tetrazine and norbornene click chemistry to enhance its structural and functional properties. The robust assembly resulted in a dual-phase material with a dense SF membrane and a porous mucin hydrogel (MH). Scanning electron microscopy confirmed the successful integration and tight adhesion between these polymers. The hybrid material exhibited a controlled release of bioactive agents, with epidermal growth factor (EGF) showing a sustained release of up to 48% over 48 h. The optimized 25 mg/mL mucin hydrogel showed efficient EGF release and performance comparable to higher concentrations. It was selected for papain loading to reduce material usage without compromising efficacy. HYB showed a higher papain release rate of 36% compared to the bare SF membrane. Additionally, the hybrid material exhibited enhanced mechanical strength, optimized water vapor permeability comparable to commercial wound dressings, and improved cell proliferation relative to its individual components. Cytotoxicity assays demonstrated that the papain-loaded hybrid material is a viable candidate for wound dressing applications. These results suggest that the click-chemistry-functionalized SF/mucin hybrid material holds significant potential as an advanced wound dressing, capable of promoting tissue regeneration while maintaining a moist environment conducive to healing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.